Evidence-based treatment of haemophilia

Haemophilia, Supplement

Volumn 10, Issue 4, 2004, Pages 20-24

  Bolton Maggs, Paula H B ^a   Stobart, K ^b   Smyth, R L ^c  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bleeding disorders; Cochrane; Evidence based medicine; Haemophilia; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; METHODOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; RELIABILITY; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW;

EID: 11044229817     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00994.x     Document Type: Article

References (21)

1. Cochrane AL. 1931-71: A critical review, with particular reference to the medical profession. In: Medicines for the Year 2000 London: Office of Health Economics, 1979; 1-11.
2. O'Mahoney B. Global Haemophilia Care: Challenge and Opportunities. Geneva: World Federation of Hemophilia, 2002.
3. Schulman S. The haemophiliac joints: new perspectives. Haemophilia 2004; 10: 114.
4. Lusher J. Hemophilia A and B. In: Lilleyman JS, Hann I, Blanchette V, eds. Pediatric Hematology. London: Churchill Livingstone. 1999; 585-600.
5. Rizza CR. Management of patients with inherited blood coagulation defects. In: Bloom AL, Thomas DP, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone. 1981; 371-88.
6. Elphick HE, Tan A, Ashby D, Smyth RL. Systematic reviews and lifelong diseases. BMJ 2002; 325: 381-4.
7. Escobar MA. Treatment on demand. In vivo dose-finding studies. Haemophilia 2003; 9: 360-7.
8. Srivastava A, Chandy M, Sunderaj GD et al. Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia. Haemophilia 1998; 4: 799-801.
9. Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 1 (Suppl. 1): 8-13.
10. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001; 7: 117-22.
11. Gringeri A, Von Mackensen S, Auerswald G et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia 2004; 10 (Suppl. 1): 26-33.
12. Manco-Johnson MJ, Blanchette VS. North American prophylaxis studies for persons with severe haemophilia: background, rationale and design. Haemophilia 2003; 9 (Suppl. 1): 44-8; discussion 49.
13. Stobart K, Wu J, eds. Clotting factor concentrates given to prevent bleeding and bleeding related complications in people with haemophilia A and B (protocol for a Cochrane review). The Cochrane Library, vol. 2. Chichester: John Wiley & Sons Ltd, 2004.
14. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club 1995; 123: A12-3.
15. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990; 263: 1385-9.
16. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
17. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-6.
18. Allen IE, Olkin I. Estimating time to conduct a meta-analysis from number of citations retrieved. JAMA 1999; 282: 634-5.
19. Seremetis S. Principles of management of hemophiliac bleeding. In: Forbes CD, Aledort LM, Madhok R, eds. Hemophilia. London: Chapman & Hall Medical. 1997; 165-9.
20. Montgomery RR, Gill JC et al. Hemophilia and von Willebrand Disease. In: Nathan DG, Orkin SH, Ginsburg D, Look AT, eds. Nathan and Oski's Hematology of Infancy and Childhood. Philadelphia: WB Saunders Co. 2003; 1547-76.
21. Nilsson IM. Hemophilia. Stockholm: Pharmacia Plasma Products, 1994.